Maxcyte (MXCT) Current Assets (2020 - 2026)

Maxcyte (MXCT) has 7 years of Current Assets data on file, last reported at $122.9 million in Q1 2026.

• Quarterly Current Assets fell 21.07% year-over-year to $122.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122.9 million (down 21.07% YoY) and the FY2025 annual result came in at $118.4 million, down 31.05% from the prior year.
• Current Assets climbed to $122.9 million in Q1 2026 per MXCT's latest filing, from $118.4 million in the prior quarter.
• Across five years, Current Assets topped out at $265.8 million in Q1 2022 and bottomed at $118.4 million in Q4 2025.
• The 5-year median for Current Assets is $178.7 million (2024), against an average of $192.9 million.
• The widest annual swing landed in 2022, when Current Assets surged 204.67%; it then tumbled 31.05% in 2025.
• Tracing MXCT's Current Assets over 5 years: stood at $252.3 million in 2022, then dropped by 24.61% to $190.2 million in 2023, then slipped by 9.73% to $171.7 million in 2024, then plunged by 31.05% to $118.4 million in 2025, then grew by 3.86% to $122.9 million in 2026.
• Per Business Quant, the three latest MXCT Current Assets figures stand at $122.9 million (Q1 2026), $118.4 million (Q4 2025), and $124.6 million (Q3 2025).

Peer Comparison